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Introduction
Germline BRCA1 or BRCA2 mutations substantially increase the risk of developing breast and ovarian cancer over those of the general population (1). The penetrance is incomplete and combined with the observed variability in age at cancer diagnosis in carriers of identical mutations, suggests the existence of genetic and/or environmental modifying factors. Direct evidence for genetic modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers has been provided through genome-wide association studies (GWAS) (2) . In parallel, multiple variants in candidate genes that affect BRCA1 or BRCA2 protein expression, act along the same biological pathways, or physically interact with BRCA1 or BRCA2 proteins have been evaluated as putative modifiers of BRCA1/2 mutations (reviewed in 3). However, only a handful of these factors were confirmed and independently validated as "true modifiers" (4) . The aim of the present study was to assess the putative modifier effect of 3,248 sequence alterations in 445 candidate genes on breast/ovarian cancer risk in 23,463 BRCA1 and BRCA2 mutation carriers.
Materials and methods

Recruitment and data collection
All study participants were women, >18 years old, carrying a deleterious germline mutation in either BRCA1 or BRCA2. DNA samples and phenotypic data were submitted by 54 study centers participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (5) . Recruitment strategies, clinical, demographic, and phenotypic data collected from each participant, and quality control procedures, have previously been reported (4, 5) . All study participants took part in research studies at the parent institutions under ethicallyapproved protocols as detailed (4, 5) .
Sequence variants genotyped
DNA samples were genotyped using the custom Illumina iCOGS array which included 211,155 single nucleotide polymorphisms (SNPs) as previously described (http://www.nature.com/icogs/primer/cogs-project-and-design-of-the-icogs-array/; 6). We report results from 3,248 SNPs from 445 candidate genes proposed by 17 PIs (=projects). The rationale for selecting the SNPs or genes as candidate cancer risk modifiers in BRCA1 and BRCA2 mutation carriers is shown in Table 1 . The list of SNPs included in the study and their gene location (if any) is provided in Supplementary Table 1 . Genotyping quality control procedures were carried out as reported elsewhere (6) .
Statistical analysis
Associations were evaluated within a retrospective cohort framework, by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes (4, 7) . The associations between genotype and breast or ovarian cancer risk were assessed using the 1 d.f. score test statistic based on this retrospective likelihood while accounting for the non-independence among related individuals (8) . All analyses were stratified by country of residence and used calendar-year and cohort-specific breast and ovarian cancer incidence rates for BRCA1 and BRCA2 mutation carriers. Details are provided elsewhere (2) .
Results
A total of 23,463 mutation carriers were included (15,252 BRCA1, 8,211 BRCA2 carriers), 12,127 with breast cancer (7,797 BRCA1, 4,330 BRCA2 carriers), 3,093 with ovarian cancer (2,462 BRCA1, 631 BRCA2 carriers), and 9,220 cancer-free carriers (5, 788 BRCA1, 3,432 BRCA2 carriers). All 3,248 SNPs were tested as genetic risk modifiers for both breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers depending on the selection rationale (Table 1) . For each SNP, the number of individuals with genotype data, minor allele frequencies (MAF), values of the X 2 score test statistic, approximate hazard ratio (HR) estimates based on the score test statistic (7) , overall P values and retrospective likelihood HR are shown in Supplementary Table 2 . Since project 12 was based on the hypothesis that estrogens contribute to breast cancer pathogenesis, these 139 SNPs were stratified by somatic estrogen receptor status (Supplementary Table 3 ). None of the SNPs tested showed significant evidence of association with breast and/or ovarian cancer risk, as a single tested variant or after adjusting for mutiple testing. Indeed, there were fewer associations at a nominal P<0.05 or P<0.01 than would be expected by chance ( Table 2 ).
Discussion
In this study, there were no discernible effects for the genotyped SNPs on either breast or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Despite the lack of evidence of association between these specific variants and breast/ovarian cancer risk for BRCA1/BRCA2 mutation carriers, these genes may still modify cancer risk by other sequence alterations that are not represented on the iCOGS platform, by epigenetic alterations in gene expression, or in combination and interaction with other polymorphisms, that in concert have an overall effect on cancer risk.
In conclusion, the genotyped SNPs in the candidate modifier genes evaluated here have no major role in breast or ovarian cancer risk modification in either BRCA1 or BRCA2 mutation carriers. Our results suggest that a candidate gene approach where the selected SNPs have little a priori biological plausibility is of limited value in identifying modifier genes, unlike agnostic genome-wide associations which have been more successful (8) . Applying more advanced technologies, (whole exome/genome sequencing) and targeting phenotypically distinct mutation carriers may also offer further insights into modifier genes" identity.
